Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Myeloproliferative neoplasms (incl. CML)
Stage/Subtype:  polycythemia vera
Country:  U.S.A.
Trial Type:  Treatment
Results 1-25 of 37 for your search:
Start Over
Graft-Versus-Host Disease Prophylaxis in Treating Patients with Hematologic Malignancies Undergoing Unrelated Donor Peripheral Blood Stem Cell Transplant
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: not specified
Trial IDs: 2448.00, NCI-2010-02035, NCT01231412
PEG-Interferon Alfa-2a or Hydroxyurea in Treating Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MPD-RC 112, NCI-2012-00269, NCT01259856
Safety and Tolerability Study of Oral NS-018 in Patients With Primary Myelofibrosis (MF), Post-polycythemia Vera MF or Post-essential Thrombocythemia MF
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: NS-018-101, NCI-2011-03576, NCT01423851
Azacitidine in Treating Patients Undergoing Matched Unrelated Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 65
Trial IDs: 201303012, NCI-2012-03105, NCT01747499
Ruxolitinib Phosphate and Decitabine in Treating Patients with Myeloproliferative Neoplasms
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MPD-RC 109, NCI-2014-01264, GCO 13-1816, MPD-RC 107, NCT02076191
Lestaurtinib in Treating Patients With Myelofibrosis
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 104, NCI-2012-00298, NCT00668421
Donor Stem Cell Transplant and T-Cell Infusion with or without Low-Intensity Preparative Chemotherapy Using Sirolimus in Treating Patients with Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 to 75
Trial IDs: 04-C-0055, NCI-2013-01407, 040055, 351967, NCI-2013-01404, NCT00077480, NCI-04-C-0055, NCT00074490
Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders
Status: Active
Phase: Phase II
Type: Treatment
Age: Any age
Trial IDs: 2056.00, NCI-2010-00237, FHCRC-2056.00, 6171, NCT00397813
Immune Response after Stem Cell Transplant in HIV-Positive Patients with Hematologic Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 75 and under
Trial IDs: 2212.00, NCI-2009-01244, 2212, NCT00968630
Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients with Hematologic Malignancies Undergoing Donor Peripheral Blood Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Age: Not specified
Trial IDs: 2206.00, NCI-2010-02222, NCT01251575
PEG-interferon Alfa-2a in Treating Patients With High Risk Polycythemia Vera or High Risk Essential Thrombocythemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MPD-RC 111, NCI-2012-00268, 111, NCT01259817
Reduced Intensity Donor Stem Cell Transplant in Treating Patients with Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 11D.247, NCI-2011-02345, 1795, 2011-31, NCT01384513
Fludarabine Phosphate, Melphalan, and Total-Body Irradiation before Donor Double Umbilical Cord Blood Transplant in Treating Patients with Hematological Malignancies
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 65
Trial IDs: 11-085, NCI-2012-00147, NCT01408563
Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis, Post Essential Thrombocythemia-myelofibrosis and Post Polycythemia Vera-myelofibrosis
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: INCB18424-258, NCI-2011-03132, NCT01348490
Ruxolitinib Phosphate and Azacytidine in Treating Patients with Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2012-0737, NCI-2013-00704, NCT01787487
Ruxolitinib Phosphate Before Reduced Intensity Donor Stem Cell Transplant in Treating Patients with Myelofibrosis
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: MPD-RC 114, NCI-2014-01258, 12-00826, 12-1809, GCO 12-1809, NCT01790295
Total-Body Irradiation, Donor Lymphocyte Infusion, and Cyclophosphamide before Donor Stem Cell Transplant in Treating Patients with High-Risk Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 13D.352, NCI-2013-02081, 2013-31, NCT01982682
LCL161 in Treating Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2013-0612, NCI-2014-01241, CLCL161AUS02T, NCT02098161
Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CLDK378AUS23, NCI-2014-02128, NCT02186821
Lorvotuzumab Mertansine in Treating Patients with Refractory CD56-Expressing Hematological Malignancies
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0926, NCI-2015-00683, NCT02420873
A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: PRM-151G-101, NCI-2013-02329, NCT01981850
Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CR107170, NCI-2015-01489, 63935937MYF2001, NCT02426086
Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: GS-US-352-1672, NCI-2015-01691, NCT02515630
Start Over